{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:22:57Z","timestamp":1790889777931,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Androgenetic alopecia (AGA) is the most common cause of hair loss in males which remains a therapeutic challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To compare the efficacy of topical 5% minoxidil and 0.25% finasteride combination (MNF) over 5% minoxidil (MNX) or 0.25% finasteride (FNS) alone by assessing hair count, physician assessment score (PAS), and patient satisfaction score (PSS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Pilot randomized open-label study where 60 male patients with AGA \u2265 III grade were randomized into three treatment groups and evaluated over 24 weeks. Improvement in hair count was assessed manually using dermoscopy. Global photographs were used to assess PAS. Side effects were evaluated using relevant laboratory investigations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At the 12\n                      <jats:sup>th<\/jats:sup>\n                      and 24\n                      <jats:sup>th<\/jats:sup>\n                      week, all three groups showed significant improvement in total hair density as compared to baseline (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). None of the groups was superior to the other (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &gt; 0.05) at the 12\n                      <jats:sup>th<\/jats:sup>\n                      week but at 24\n                      <jats:sup>th<\/jats:sup>\n                      week, MNF was comparatively superior (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.02). At the 12\n                      <jats:sup>th<\/jats:sup>\n                      week and 24\n                      <jats:sup>th<\/jats:sup>\n                      week, all three groups showed significant improvement in terminal hair density as compared to baseline (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). In the 12\n                      <jats:sup>th<\/jats:sup>\n                      week, MNF was comparatively superior (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.028) and at the 24\n                      <jats:sup>th<\/jats:sup>\n                      week, MNF was comparatively superior (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.02). PAS and PSS were significantly better with MNF and MNX compared to FNS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.004). Side effects such as scaling and itching were reported with MNF and MNX.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Topical minoxidil 5% and finasteride 0.25% had an overall better efficacy compared to monotherapy without significant side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijt.ijt_72_22","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:14:26Z","timestamp":1690474466000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Comparative Efficacy of Topical Finasteride (0.25%) in Combination with Minoxidil (5%) Against 5% Minoxidil or 0.25% Finasteride Alone in Male Androgenetic Alopecia"],"prefix":"10.4103","volume":"15","author":[{"given":"Apoorva V","family":"Bharadwaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhu","family":"Mendiratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmeet Singh","family":"Rehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240903","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0733-8635(05)70396-X","article-title":"Androgen metabolism as it affects hair growth in androgenetic alopecia","volume":"14","author":"Kaufman","year":"1996","journal-title":"Dermatol Clin"},{"key":"R2-3-20240903","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1210\/jcem-38-5-811","article-title":"Regulation of human hair growth by steroid hormones. I. Testerone metabolism in isolated hairs","volume":"38","author":"Schweikert","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"R3-3-20240903","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4103\/0378-6323.116730","article-title":"Androgenetic alopecia:An update","volume":"79","author":"Kaliyadan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R4-3-20240903","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jdv.15171","article-title":"A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia","volume":"32","author":"Suchonwanit","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-3-20240903","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/00007611-197511000-00009","article-title":"Male pattern baldness:Classification and incidence","volume":"68","author":"Norwood","year":"1975","journal-title":"South Med J"},{"key":"R6-3-20240903","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.4065\/80.10.1316","article-title":"Psychological effect, pathophysiology, and management of androgenetic alopecia in men","volume":"80","author":"Stough","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"R7-3-20240903","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0190-9622(98)70007-6","article-title":"Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group","volume":"39","author":"Kaufman","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R8-3-20240903","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2002.124088","article-title":"Arandomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men","volume":"47","author":"Olsen","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R9-3-20240903","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/09546634.2019.1654070","article-title":"Efficacy and safety of a new 10% topical minoxidil versus 5% topical minoxidil and placebo in the treatment of male androgenetic alopecia:A trichoscopic evaluation","volume":"32","author":"Ghonemy","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"R10-3-20240903","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/1523-1747.ep12335779","article-title":"Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia","volume":"109","author":"Sawaya","year":"1997","journal-title":"J Invest Dermatol"},{"key":"R11-3-20240903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399402005112","article-title":"Androgenetic alopecia:Pathogenesis and potential for therapy","volume":"4","author":"Ellis","year":"2002","journal-title":"Expert Rev Mol Med"},{"key":"R12-3-20240903","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1126\/science.186.4170.1213","article-title":"Steroid 5alpha-reductase deficiency in man:An inherited form of male pseudohermaphroditism","volume":"186","author":"Imperato-McGinley","year":"1974","journal-title":"Science"},{"key":"R13-3-20240903","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0190-9622(99)70081-2","article-title":"Finasteride in the treatment of men with frontal male pattern hair loss","volume":"40","author":"Leyden","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R15-3-20240903","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jnci\/djm023","article-title":"Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial","volume":"99","author":"Moinpour","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R16-3-20240903","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","article-title":"Persistent sexual side effects of finasteride for male pattern hair loss","volume":"8","author":"Irwig","year":"2011","journal-title":"J Sex Med"},{"key":"R17-3-20240903","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome:A surmountable challenge for clinicians","volume":"113","author":"Traish","year":"2020","journal-title":"Fertil Steril"},{"key":"R18-3-20240903","doi-asserted-by":"crossref","first-page":"842","DOI":"10.5414\/CP202119","article-title":"A novel finasteride 0.25% topical solution for androgenetic alopecia:Pharmacokinetics and effects on plasma androgen levels in healthy male volunteers","volume":"52","author":"Caserini","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R19-3-20240903","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0378-6323.45220","article-title":"Comparing the therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia","volume":"75","author":"Hajheydari","year":"2009","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R20-3-20240903","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/09546639709160517","article-title":"Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course","volume":"8","author":"Mazzarella","year":"1997","journal-title":"J Dermatol Treat"},{"key":"R21-3-20240903","first-page":"457","article-title":"A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women","volume":"17","author":"Lee","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R22-3-20240903","first-page":"1312","article-title":"Efficacy and safety of 3% minoxidil versus combined 3% minoxidil\/0.1% finasteride in male pattern hair loss:A randomized, double-blind, comparative study","volume":"95","author":"Tanglertsampan","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"R23-3-20240903","doi-asserted-by":"crossref","first-page":"241953","DOI":"10.5402\/2011\/241953","article-title":"Pilot study of 15 patients receiving a new treatment regimen for androgenic alopecia:The effects of atopy on AGA","volume":"2011","author":"Rafi","year":"2011","journal-title":"ISRN Dermatol"},{"key":"R24-3-20240903","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4103\/2229-5178.148925","article-title":"Topical minoxidil fortified with finasteride:An account of maintenance of hair density after replacing oral finasteride","volume":"6","author":"Chandrashekar","year":"2015","journal-title":"Indian Dermatol Online J"},{"key":"R25-3-20240903","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1346-8138.2002.tb00314.x","article-title":"Comparative efficacy of various treatment regimens for androgenetic alopecia in men","volume":"29","author":"Khandpur","year":"2002","journal-title":"J Dermatol"},{"key":"R26-3-20240903","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1610-0379.2011.07802.x","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men","volume":"9","author":"Blumeyer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"R27-3-20240903","doi-asserted-by":"crossref","first-page":"4.e13","DOI":"10.1016\/j.fertnstert.2010.12.061","article-title":"Finasteride-induced secondary infertility associated with sperm DNA damage","volume":"95","author":"Tu","year":"2011","journal-title":"Fertil Steril"},{"key":"R28-3-20240903","doi-asserted-by":"crossref","first-page":"11.e9","DOI":"10.1016\/j.fertnstert.2010.12.001","article-title":"Finasteride-associated male infertility","volume":"95","author":"Chiba","year":"2011","journal-title":"Fertil Steril"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_72_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:16:03Z","timestamp":1787760963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_72_22"}},"subtitle":["A Pilot, Randomized Open-Label Study"],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_72_22","relation":{},"ISSN":["0974-7753"],"issn-type":[{"value":"0974-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}